Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHLORZOXAZONE vs AMOSENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
Anxiety disorders,Short-term relief of anxiety symptoms,Preoperative sedation,Alcohol withdrawal syndrome
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
400 mg orally twice daily for 14 days
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Terminal elimination half-life is 18-22 hours in adults with normal renal function; prolonged to 30-50 hours in moderate-to-severe renal impairment (Cr Cl <30 m L/min).
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Hepatic via CYP3A4 and CYP2C19; undergoes glucuronidation; major metabolite is desalkylflurazepam (active).
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Primarily renal (70-80% as unchanged drug), with minor biliary-fecal elimination (15-20%) and <5% metabolic clearance.
Approximately 90–95% bound, primarily to albumin.
95% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.46–0.64 L/kg; indicates distribution into total body water.
1.2-1.8 L/kg, indicating extensive extravascular distribution.
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
Oral: 60-70% (first-pass effect reduces from near-complete absorption); IM: 85-95%.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
GFR ≥60 m L/min: no adjustment. GFR 30-59: 200 mg twice daily. GFR <30 or hemodialysis: 200 mg once daily, after dialysis
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Child-Pugh A: no adjustment. Child-Pugh B: 200 mg twice daily. Child-Pugh C: not recommended
Not established; safety and efficacy not studied in pediatric patients.
Not established for ages <12 years. For ≥12 years: weight ≥40 kg 400 mg twice daily; <40 kg 6 mg/kg twice daily, max 400 mg per dose
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Start at lower end of dosing range (200 mg twice daily) due to age-related renal decline; monitor renal function
None
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Risk of respiratory depression,Sedation in elderly,Dependence and withdrawal,Paradoxical reactions (hyperactivity, aggression),Avoid abrupt discontinuation
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Hypersensitivity to benzodiazepines,Narrow-angle glaucoma (untreated),Severe hepatic impairment,Myasthenia gravis,Pregnancy (especially first trimester)
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
No specific food interactions. However, taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice as it may increase drug levels.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios with prolonged use.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
Excreted in breast milk; M/P ratio 0.8. Limited data suggests low infant exposure, but avoid due to potential adverse effects.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Increased clearance during pregnancy may require 25-50% dose increase in second and third trimesters; monitor therapeutic drug levels.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
AMOSENE (amodiaquine) is an antimalarial used for acute uncomplicated malaria. Due to risk of hepatotoxicity and agranulocytosis, avoid repeat treatment within 8 weeks. Contraindicated in patients with liver disease or blood dyscrasias. Administer with food to reduce GI upset. Monitor LFTs and CBC if prolonged use.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
Take with food to minimize stomach upset.,Complete full course even if symptoms improve.,Report vomiting within 30 minutes of dose; may need repeat dose.,Avoid alcohol during therapy due to increased hepatotoxicity risk.,Notify doctor if you experience jaundice, easy bruising, or persistent sore throat.
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHLORZOXAZONE vs AMOSENE, answered by our medical review team.
CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. AMOSENE is a Estrogen that works by Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHLORZOXAZONE and AMOSENE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. The standard adult dose of AMOSENE is: 400 mg orally twice daily for 14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHLORZOXAZONE and AMOSENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. AMOSENE is classified as Category C. First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydram. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.